Sareum Holdings PLC Full Year Results Investor Presentation (8441B)
13 October 2020 - 5:01PM
UK Regulatory
TIDMSAR
RNS Number : 8441B
Sareum Holdings PLC
13 October 2020
Sareum Holdings PLC
("Sareum" or the "Company")
INVESTOR PRESENTATION
Cambridge, UK, 13 October 2020 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, is pleased to announce that, further to
today's Final Results announcement, Dr Tim Mitchell will deliver a
live online presentation to investors via the Investor Meet Company
("IMC") platform at 10.00 a.m. on Friday, 16 October 2020.
Existing and potential investors wishing to participate in the
presentation should register with IMC at:
www.investormeetcompany.com/sareum-holdings-plc/register-investor.
Investors who have already registered with IMC and requested to
meet the Company will be invited automatically.
Questions can be submitted before the event via the IMC
dashboard or at any time during the live presentation via the "Ask
a Question" function. Although the Company may not be able to
answer every question it receives, it will seek to address the most
prominent questions within the confines of information already
disclosed to the market. Responses from the Q&A session will be
published at the earliest opportunity on the IMC platform.
A copy of the presentation will be made available on the
Company's website following the presentation.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow/ David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the "cytokine storm" immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
is currently exploring options to obtain the funding or support
necessary to advance the future development of SRA737.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com.
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPGWPUUPUGQP
(END) Dow Jones Newswires
October 13, 2020 02:01 ET (06:01 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024